Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Danaher Corporation designs, manufactures, and markets professional, medical, industrial and commercial products, and services in the sectors of test and measurement, environmental, life sciences, dental, and industrial technologies.
Website: danaher.com


  • Pretty weak financial results growth rate 4.7% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-4.9%)
  • Dividend yield for the last twelve months 0.7%
  • Free cash flow yield 1.1% (LTM)
  • Share price is 11.1% higher than minimum and 35.9% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (26.6x vs 30.0x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.2 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: DHR
Share price, USD:  (-1.5%)179.87
year average price 204.56  


year start price 189.23 2025-06-02

max close price 242.05 2026-01-21

min close price 161.91 2026-05-15

current price 179.87 2026-06-02
Common stocks: 727 076 992

Dividend Yield:  0.7%
FCF Yield LTM: 1.1%
EV / LTM EBITDA: 26.6x
EV / EBITDA annualized: 21.7x
Last revenue growth (y/y):  +4.6%
Last growth of EBITDA (y/y):  +4.8%
Historical revenue growth:  +0.6%
Historical growth of EBITDA:  -10.5%
EV / Sales: 5.9x
Margin (EBITDA LTM / Revenue): 22.1%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 130 779
Net Debt ($m): 13 810
EV (Enterprise Value): 144 589
EBITDA LTM (млн $): 5 432
EV / LTM EBITDA: 26.6x
Price to Book: 2.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-30seekingalpha.com

Danaher Stock Plunge Does Not Represent A Good Entry Point

2026-01-28zacks.com

Danaher Q4 Earnings Beat Estimates, Life Sciences Sales Up Y/Y

2026-01-28zacks.com

Danaher (DHR) Beats Q4 Earnings and Revenue Estimates

2026-01-28reuters.com

Danaher forecasts 2026 profit in line with estimates on pharma spending recovery

2026-01-23zacks.com

Insights Into Danaher (DHR) Q4: Wall Street Projections for Key Metrics

2026-01-23zacks.com

Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?

2026-01-21zacks.com

Danaher (DHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

2026-01-13seekingalpha.com

Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-13seekingalpha.com

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

2025-12-24prnewswire.com

HALPER SADEH LLC ENCOURAGES DANAHER CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-26 2025-06-27 2024-12-31 2024-09-27 2024-06-28 2024-03-29 2023-12-31 2023-09-29 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616
fillingDate 2025-10-21 2025-07-22 2024-10-22 2024-07-23 2024-04-23 2023-10-24 2023-07-25 2023-04-25 2022-10-20
acceptedDate 2025-10-20 17:56:13 2025-07-21 18:39:11 2025-02-20 16:18:06 2024-10-21 17:38:16 2024-07-22 17:41:46 2024-04-22 17:53:08 2024-02-21 16:38:09 2023-10-23 17:43:27 2023-07-24 17:46:33 2023-04-24 17:55:09 2023-02-22 16:40:48 2022-10-19 17:49:34 2022-02-23 16:49:10 2021-02-24 19:13:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 6 053M 5 936M 23 875M 5 798M 5 743M 5 796M 23 890M 6 873M 7 157M 7 167M 26 643M 7 663M 29 453M 22 284M
costOfRevenue 2 530M 1 981M 9 669M 2 397M 2 315M 2 309M 9 856M 2 873M 3 116M 2 797M 10 455M 3 079M 11 501M 9 809M
grossProfit 3 523M 3 955M 14 206M 3 401M 3 428M 3 487M 14 034M 4 000M 4 041M 4 370M 16 188M 4 584M 17 952M 12 475M
grossProfitRatio 0.582 0.666 0.587 0.597 0.602 0.582 0.565 0.61 0.598
researchAndDevelopmentExpenses 378M 403M 1 584M 383M 391M 368M 1 503M 417M 418M 429M 1 528M 420M 1 742M 1 348M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 1 991M 2 360M 7 438M 2 060M 1 869M 1 807M 7 252M 2 145M 2 194M 2 147M 7 124M 2 149M 8 160M 6 815M
otherExpenses 0 0 0 0 0 1 000 000 0 1 000 000 -29M 2M 0 0 0 0
operatingExpenses 2 369M 2 763M 9 022M 2 443M 2 260M 2 175M 8 755M 2 562M 2 612M 2 576M 8 652M 2 569M 9 902M 8 163M
costAndExpenses 4 899M 4 744M 18 691M 4 840M 4 575M 4 484M 18 611M 5 435M 5 728M 5 373M 19 107M 5 648M 21 403M 17 972M
interestIncome 3M 8M 117M 4M 39M 60M 303M 79M 59M 48M 41M 9M 11M 71M
interestExpense 67M 71M 278M 87M 65M 65M 289M 73M 67M 68M 207M 42M 241M 273M
depreciationAndAmortization 622M 611M 2 352M 591M 580M 586M 2 166M 554M 562M 607M 2 132M 498M 2 168M 1 775M
ebitda 1 765M 1 337M 7 276M 1 655M 1 748M 1 898M 7 499M 2 072M 1 459M 2 401M 9 485M 2 513M 10 007M 6 543M
ebitdaratio 0.292 0.225 0.285 0.304 0.327 0.301 0.204 0.335 0.328
operatingIncome 1 154M 1 192M 5 184M 958M 1 168M 1 312M 5 279M 1 438M 897M 1 794M 7 536M 2 015M 8 050M 4 312M
operatingIncomeRatio 0.191 0.201 0.165 0.203 0.226 0.209 0.125 0.25 0.263
totalOtherIncomeExpensesNet -78M -537M -538M 19M -85M -41M -235M -47M 495M 4M -390M -84M -452M 183M
incomeBeforeTax 1 076M 655M 4 646M 977M 1 083M 1 271M 5 044M 1 397M 1 392M 1 798M 7 146M 1 931M 7 598M 4 495M
incomeBeforeTaxRatio 0.178 0.11 0.169 0.189 0.219 0.203 0.194 0.251 0.252
incomeTaxExpense 168M 100M 747M 159M 176M 183M 823M 268M 286M 348M 818M 359M 1 251M 849M
netIncome 908M 555M 3 899M 818M 907M 1 088M 4 764M 1 129M 1 106M 1 450M 7 209M 1 572M 6 433M 3 646M
netIncomeRatio 0.15 0.093 0.141 0.158 0.188 0.164 0.155 0.202 0.205
eps 1.28 0.77 5.33 1.13 1.23 1.47 6.44 1.53 1.5 1.96 9.8 2.13 8.77 4.97
epsdiluted 1.27 0.77 1.12 1.22 1.45 1.51 1.49 1.94 2.1
weightedAverageShsOut 711M 717M 731M 723M 738M 741M 737M 739M 737M 729M 725M 729M 715M 706M
weightedAverageShsOutDil 714M 719M 737M 729M 742M 749M 743M 746M 745M 737M 737M 737M 737M 719M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-20 2024-02-21 2023-02-22 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -161M 14M -166M -230M -202M
ebit 4 924M 5 333M 7 353M 7 839M 4 768M
nonOperatingIncomeExcludingInterest 260M -54M 183M 211M -456M
netIncomeFromContinuingOperations 3 899M 4 221M 6 328M 6 347M 3 646M
netIncomeFromDiscontinuedOperations 0 543M 881M 86M 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 -78M -1 000 000
bottomLineNetIncome 3 899M 4 743M 7 103M 6 347M 3 511M
epsDiluted 5.29 6.38 9.64 8.61 4.89

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-26 2025-06-27 2024-12-31 2024-09-27 2024-06-28 2024-03-29 2023-12-31 2023-09-29 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616
fillingDate 2025-10-21 2025-07-22 2024-10-22 2024-07-23 2024-04-23 2023-10-24 2023-07-25 2023-04-25 2022-10-20
acceptedDate 2025-10-20 17:56:13 2025-07-21 18:39:11 2025-02-20 16:18:06 2024-10-21 17:38:16 2024-07-22 17:41:46 2024-04-22 17:53:08 2024-02-21 16:38:09 2023-10-23 17:43:27 2023-07-24 17:46:33 2023-04-24 17:55:09 2023-02-22 16:40:48 2022-10-19 17:49:34 2022-02-23 16:49:10 2021-02-24 19:13:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 528M 2 957M 2 078M 2 627M 2 374M 7 031M 5 864M 12 277M 8 575M 7 379M 5 995M 5 150M 2 586M 6 035M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 1 528M 2 957M 2 078M 2 627M 2 374M 7 031M 5 864M 12 277M 8 575M 7 379M 5 995M 5 150M 2 586M 6 035M
netReceivables 3 755M 4 516M 4 390M 3 507M 3 298M 3 379M 4 637M 4 201M 4 199M 4 313M 5 064M 4 409M 5 443M 4 810M
inventory 2 674M 2 689M 2 330M 2 678M 2 671M 2 645M 2 594M 3 024M 3 183M 3 383M 2 765M 3 236M 2 767M 2 292M
otherCurrentAssets 1 649M 837M 79M 1 248M 1 266M 1 317M 71M 1 703M 1 504M 1 457M 1 359M 1 455M 82M 665M
totalCurrentAssets 9 606M 10 999M 9 497M 10 060M 9 609M 14 372M 13 937M 21 205M 17 461M 16 532M 15 883M 14 250M 11 648M 13 802M
propertyPlantEquipmentNet 5 376M 6 409M 6 074M 4 843M 5 743M 5 662M 5 605M 4 302M 4 176M 4 065M 4 593M 3 719M 4 831M 4 204M
goodwill 42 948M 42 991M 40 497M 42 173M 40 805M 40 846M 41 608M 39 155M 39 576M 39 856M 37 276M 38 251M 41 184M 35 420M
intangibleAssets 18 097M 18 629M 18 568M 19 854M 19 545M 19 888M 20 746M 18 786M 19 317M 19 976M 19 821M 19 964M 22 843M 21 282M
goodwillAndIntangibleAssets 61 045M 61 620M 59 065M 62 027M 60 350M 60 734M 62 354M 57 941M 58 893M 59 832M 57 097M 58 215M 64 027M 56 702M
longTermInvestments 0 1 484M 1 815M 1 702M 476M 370M 1 696M 4M 0 0 2 164M 0 1 320M 27M
taxAssets 0 0 0 0 0 0 0 -4M 0 0 0 0 0 0
otherNonCurrentAssets 3 870M 1 108M 1 091M 1 983M 2 377M 2 264M 896M 4 286M 4 372M 4 611M 4 613M 4 846M 1 358M 1 426M
totalNonCurrentAssets 70 291M 70 621M 68 045M 70 555M 68 946M 69 030M 70 551M 66 529M 67 441M 68 508M 68 467M 66 780M 71 536M 62 359M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 79 897M 81 620M 77 542M 80 615M 78 555M 83 402M 84 488M 87 734M 84 902M 85 040M 84 350M 81 030M 83 184M 76 161M
accountPayables 1 698M 1 725M 1 753M 1 596M 1 645M 1 679M 1 766M 1 894M 1 956M 2 081M 1 856M 2 191M 2 569M 2 049M
shortTermDebt 23M 1 702M 505M 1 200M 701M 2 846M 1 875M 2 547M 1 590M 1 571M 758M 705M 215M 200M
taxPayables 0 0 0 0 0 0 582M 0 0 0 691M 0 707M 552M
deferredRevenue 0 0 1 299M 0 0 0 1 465M 0 0 0 1 456M 0 1 613M 1 212M
otherCurrentLiabilities 4 603M 3 365M 1 343M 4 543M 4 355M 3 253M 1 402M 4 926M 4 858M 5 078M 2 476M 5 106M 1 593M 1 927M
totalCurrentLiabilities 6 324M 6 792M 6 798M 7 339M 6 701M 7 778M 8 274M 9 367M 8 404M 8 730M 8 389M 8 002M 8 140M 7 402M
longTermDebt 16 833M 16 853M 15 500M 16 324M 17 509M 16 417M 16 707M 19 513M 18 285M 18 261M 19 086M 18 542M 22 168M 21 193M
deferredRevenueNonCurrent 0 0 232M 0 0 0 249M 0 0 0 221M 0 213M 205M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 5 669M 5 633M 4 494M 5 647M 4 443M 5 760M 4 814M 6 439M 6 489M 6 563M 5 792M 23 139M 6 597M 6 799M
totalNonCurrentLiabilities 22 502M 22 486M 21 194M 21 971M 21 952M 22 177M 22 724M 25 952M 24 774M 24 824M 25 871M 26 035M 29 867M 28 982M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 1 141M 0 1 200M 1 100M 954M 1 100M 0 0 772M 0 889M 785M
totalLiabilities 28 826M 29 278M 27 992M 29 310M 28 653M 29 955M 30 998M 35 319M 33 178M 33 554M 34 260M 34 037M 38 007M 36 384M
preferredStock 0 0 0 0 0 0 0 0 0 1 668M 1 668M 1 668M 3 268M 3 268M
commonStock 9M 9M 9M 9M 9M 9M 9M 9M 9M 9M 9M 9M 9M 9M
retainedEarnings 45 920M 45 239M 44 188M 43 296M 42 673M 41 962M 41 074M 42 272M 41 344M 40 437M 39 205M 37 177M 32 827M 27 159M
accumulatedOtherComprehensiveIncomeLoss -590M -569M -3 218M -1 310M -2 591M -2 744M -1 748M -3 959M -3 576M -2 766M -2 872M -3 854M -1 027M -368M
othertotalStockholdersEquity 5 732M 7 655M 9 304M 9 806M 14 215M 14 085M 13 939M 12 130M 11 985M
totalStockholdersEquity 51 071M 52 334M 49 543M 51 299M 49 897M 53 442M 53 486M 52 407M 51 716M 51 478M 50 082M 46 985M 45 167M 39 766M
totalEquity 51 080M 52 342M 49 550M 51 305M 49 902M 53 447M 53 490M 52 415M 51 724M 51 478M 50 090M 46 985M 45 177M 39 777M
totalLiabilitiesAndStockholdersEquity 79 897M 81 620M 80 615M 78 555M 83 402M 87 734M 84 902M 85 040M 81 022M
minorityInterest 9M 8M 7M 6M 5M 5M 4M 8M 8M 8M 8M 0 10M 11M
totalLiabilitiesAndTotalEquity 79 897M 81 620M 77 542M 80 615M 78 555M 83 402M 84 488M 87 734M 84 902M 85 040M 84 350M 81 022M 83 184M 76 161M
totalInvestments 0 1 484M 1 815M 1 702M 476M 370M 1 696M 4M 0 0 2 164M 0 1 320M 27M
totalDebt 16 856M 18 555M 17 146M 17 524M 18 210M 19 263M 19 536M 22 060M 19 875M 19 832M 20 616M 19 247M 23 272M 22 178M
netDebt 15 328M 15 598M 15 068M 14 897M 15 836M 12 232M 13 672M 9 783M 11 300M 12 453M 14 621M 14 097M 20 686M 16 143M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-20 2024-02-21 2023-02-22 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 3 537M 3 922M 4 102M 4 631M 4 110M
otherReceivables 853M 715M 962M 812M 700M
prepaids 620M 771M 700M 770M 0
totalPayables 2 321M 2 348M 2 477M 3 276M 2 601M
otherPayables 568M 582M 621M 707M 552M
accruedExpenses 1 157M 1 184M 1 222M 1 443M 1 462M
capitalLeaseObligationsCurrent 173M 0 0 0 0
capitalLeaseObligationsNonCurrent 968M 954M 772M 889M 785M
treasuryStock -8 163M 0 0 0 0
additionalPaidInCapital 16 727M 14 151M 12 072M 10 090M 9 698M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-26 2025-06-27 2024-12-31 2024-09-27 2024-06-28 2024-03-29 2023-12-31 2023-09-29 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR DHR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616 313 616
fillingDate 2025-10-21 2025-07-22 2024-10-22 2024-07-23 2024-04-23 2023-10-24 2023-07-25 2023-04-25 2022-10-20
acceptedDate 2025-10-20 17:56:13 2025-07-21 18:39:11 2025-02-20 16:18:06 2024-10-21 17:38:16 2024-07-22 17:41:46 2024-04-22 17:53:08 2024-02-21 16:38:09 2023-10-23 17:43:27 2023-07-24 17:46:33 2023-04-24 17:55:09 2023-02-22 16:40:48 2022-10-19 17:49:34 2022-02-23 16:49:10 2021-02-24 19:13:25
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 908M 555M 3 899M 818M 907M 1 088M 4 221M 1 129M 1 106M 1 450M 7 209M 1 572M 6 347M 3 646M
depreciationAndAmortization 723M 611M 2 352M 591M 580M 586M 2 166M 554M 562M 557M 2 222M 540M 2 168M 1 775M
deferredIncomeTax 0 0 0 0 0 -324M 0 0 0 0 -559M 0 -318M -462M
stockBasedCompensation 0 91M 288M 84M 87M 60M 306M 92M 109M 79M 295M 89M 184M 187M
changeInWorkingCapital 0 -395M 266M -99M -216M -57M -393M -151M 117M -117M -1 519M -255M -658M 605M
accountsReceivables -199M 45M 331M 0 74M 516M 322M -56M 134M 631M -477M 11M -611M -264M
inventory 6M -82M 147M 35M -34M -118M 185M 103M 129M -257M -486M -61M -502M -123M
accountsPayables -23M -50M 19M -82M -30M -74M -149M -36M -135M -228M 5M -169M 549M 227M
otherWorkingCapital 216M -308M -231M -52M -226M -381M -751M -162M -11M -263M -561M -36M -94M 765M
otherNonCashItems 31M 476M -117M 119M 1 296M 970M 864M 48M 32M -22M 830M 64M 601M 457M
netCashProvidedByOperatingActivities 1 662M 1 338M 6 688M 1 513M 1 417M 1 739M 7 164M 1 672M 1 926M 1 947M 8 519M 2 010M 8 358M 6 208M
investmentsInPropertyPlantAndEquipment -292M -248M -1 392M -298M -287M -291M -1 383M -365M -341M -275M -1 152M -277M -1 294M -791M
acquisitionsNet 0 0 0 -502M -11M 0 -5 610M 4M 4M 42M -637M -227M -10 935M -20 145M
purchasesOfInvestments -29M 0 -331M -61M -74M -53M -172M -8M -101M -43M -523M -26M -934M -342M
salesMaturitiesOfInvestments 2M 0 253M 242M 0 9M 61M 29M 3M 1 000 000 18M 1 000 000 126M 13M
otherInvestingActivites 7M -10M 13M 12M 14M 11M 4M -29M 14M
netCashUsedForInvestingActivites -312M -258M -606M -360M -321M -329M -431M -304M -515M
debtRepayment 475M 2M -14M -1 027M -68M -2 603M 0 -4M 0
commonStockIssued 25M 19M 0 0 -1 000 000 55M 0 -34M 0
commonStockRepurchased -1 985M 0 -5 979M -640M -4 530M 0 0 -2 658M 0 38M 0 0 0 0
dividendsPaid -229M -229M -196M -200M -177M -199M -218M -204M -204M
otherFinancingActivites -1 010M -39M 5M 42M -23M 7 848M 10M -58M -26M
netCashUsedProvidedByFinancingActivities -2 724M -247M -845M -5 715M -133M 2 443M -208M -262M -230M
effectOfForexChangesOnCash 592M 131M -108M 191M 1 000 000 -118M 59M -84M -91M 3M -306M -99M -115M 148M
netChangeInCash -782M 964M -3 786M 253M -4 657M 1 167M -131M 3 702M 1 196M 1 384M 3 409M 1 166M -3 449M -13 877M
cashAtEndOfPeriod 1 518M 2 957M 2 078M 2 627M 2 374M 7 031M 5 864M 12 277M 8 575M 7 379M 5 995M 5 150M 2 586M 6 035M
cashAtBeginningOfPeriod 2 300M 1 993M 5 864M 2 374M 7 031M 5 864M 5 995M 8 575M 7 379M 5 995M 2 586M 3 984M 6 035M 19 912M
operatingCashFlow 1 662M 1 338M 6 688M 1 513M 1 417M 1 739M 7 164M 1 672M 1 926M 1 947M 8 519M 2 010M 8 358M 6 208M
capitalExpenditure -292M -248M -1 392M -298M -287M -291M -1 383M -365M -341M -275M -1 152M -277M -1 294M -791M
freeCashFlow 1 370M 1 090M 5 296M 1 215M 1 130M 1 448M 5 781M 1 307M 1 585M 1 672M 7 367M 1 733M 7 064M 5 417M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-20 2024-02-21 2023-02-22 2022-02-23 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -511M 23M 60M 50M 26M
netCashProvidedByInvestingActivities -1 981M -7 081M -2 234M -12 987M -21 239M
netDebtIssuance -1 669M -1 626M -1 688M 1 967M -1 900M
longTermNetDebtIssuance -1 674M -620M -965M -298M 2 737M
shortTermNetDebtIssuance 5M -1 006M -723M 2 265M -4 637M
netStockIssuance -5 817M 68M 31M 86M 3 550M
netCommonStockIssuance -5 817M 68M 31M 86M 1 882M
commonStockIssuance 162M 68M 31M 86M 1 882M
netPreferredStockIssuance 0 0 0 0 1 668M
netDividendsPaid -768M -821M -818M -742M -615M
commonDividendsPaid -768M -821M -818M -742M -615M
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -131M 2 106M -95M -16M -29M
netCashProvidedByFinancingActivities -8 385M -273M -2 570M 1 295M 1 006M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q4
2026-01-28 ET (fiscal 2025 q4)
2025 q3
2025-10-21 ET (fiscal 2025 q3)
2025 q2
2025-07-22 ET (fiscal 2025 q2)
2025 q1
2025-04-22 ET (fiscal 2025 q1)
2024 q4
2025-01-29 ET (fiscal 2024 q4)
2024 q3
2024-10-22 ET (fiscal 2024 q3)
2024 q2
2024-07-23 ET (fiscal 2024 q2)
2024 q1
2024-04-23 ET (fiscal 2024 q1)
2023 q4
2024-01-30 ET (fiscal 2023 q4)
2023 q3
2023-10-24 ET (fiscal 2023 q3)
2023 q2
2023-07-25 ET (fiscal 2023 q2)
2023 q1
2023-04-25 ET (fiscal 2023 q1)
2022 q4
2023-01-24 ET (fiscal 2022 q4)
2022 q3
2022-10-20 ET (fiscal 2022 q3)
2022 q2
2022-07-21 ET (fiscal 2022 q2)
2022 q1
2022-04-21 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-06 20:15 ET
Danaher to Present at Bank of America Securities Healthcare Conference
2026-05-05 20:30 ET
Danaher Announces Quarterly Dividend
2026-05-04 13:00 ET
Masimo Shareholders Approve Acquisition by Danaher
2026-04-22 ET
Danaher Announces Pricing of Euro-Denominated Senior Notes Offering
2026-04-21 ET
Danaher Reports First Quarter 2026 Results
2026-04-13 ET
Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes
2026-03-20 ET
Danaher Schedules First Quarter 2026 Earnings Conference Call
2026-02-24 ET
Danaher Announces Quarterly Dividend
2026-02-24 ET
Danaher to Present at TD Cowen Health Care Conference
2026-01-28 11:00 ET
Danaher Reports Fourth Quarter and Full Year 2025 Results
2026-01-12 ET
Danaher CEO to Comment on Financial Performance
2026-01-05 ET
Danaher to Present at J.P. Morgan Healthcare Conference
2025-12-17 ET
Danaher Schedules Fourth Quarter 2025 Earnings Conference Call
2025-12-09 ET
Danaher Announces Quarterly Dividend
2025-11-11 ET
Danaher to Present at Jefferies Global Healthcare Conference
2025-10-21 ET
Danaher Reports Third Quarter 2025 Results
2025-09-23 ET
Danaher Schedules Third Quarter 2025 Earnings Conference Call
2025-09-10 ET
Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research
2025-09-09 ET
Danaher Announces Quarterly Dividend
2025-09-09 ET
Danaher Corporation (NYSE: DHR) Investor Alert: Schubert Jonckheer Investigating Possible False Claims, $73 Million in Stock Sales
2025-07-31 ET
Danaher Appoints Jonathan Leiken as General Counsel
2025-07-22 ET
Danaher Announces Transition Plan for Chief Financial Officer
2025-07-22 ET
Danaher Reports Second Quarter 2025 Results
2025-06-27 ET
Danaher Appoints Martin Stumpe as Chief Technology and AI Officer
2025-06-27 ET
Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences
2025-06-17 ET
Danaher Schedules Second Quarter 2025 Earnings Conference Call
2025-06-02 ET
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
2025-06-02 ET
Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations
2025-06-02 ET
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
2025-05-15 ET
Aldevron and Integrated DNA Technologies Manufacture World’s First mRNA-based Personalized CRISPR Therapy
2025-05-07 ET
Danaher to Present at Bank of America Securities Healthcare Conference
2025-05-06 ET
Danaher Announces Quarterly Dividend
2025-04-29 ET
Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
2025-04-22 ET
Danaher Reports First Quarter 2025 Results
2025-03-20 ET
Danaher Schedules First Quarter 2025 Earnings Conference Call
2025-03-10 ET
Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System
2025-02-25 ET
Danaher to Present at TD Cowen Health Care Conference
2025-02-20 ET
Danaher Announces Appointment of Charles Lamanna to Danaher Board
2025-02-20 ET
Danaher Increases Quarterly Dividend
2025-01-29 ET
Danaher Reports Fourth Quarter and Full Year 2024 Results
2025-01-21 ET
Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications
2025-01-15 ET
Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research
2025-01-13 ET
Danaher CEO to Comment on Financial Performance
2025-01-09 ET
Danaher Announces Investment Partnership in Innovaccer Inc.
2025-01-06 ET
Danaher to Present at J.P. Morgan Healthcare Conference
2025-01-02 ET
Danaher Schedules Fourth Quarter 2024 Earnings Conference Call
2024-12-10 ET
Danaher Announces Quarterly Dividend
2024-11-26 ET
Danaher to Present at Evercore ISI HealthCONx Conference
2024-10-22 10:00 ET
Danaher Reports Third Quarter 2024 Results
2024-09-19 20:30 ET
Danaher Schedules Third Quarter 2024 Earnings Conference Call
2024-09-17 12:30 ET
Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
2024-09-10 20:15 ET
Danaher Announces Quarterly Dividend
2024-07-25 13:00 ET
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration
2024-07-23 10:00 ET
Danaher Reports Second Quarter 2024 Results
2024-07-17 11:30 ET
Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development
2024-07-16 11:30 ET
Danaher Releases 2024 Sustainability Report
2024-07-11 11:30 ET
Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening
2024-07-09 07:00 ET
Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer
2024-06-24 20:30 ET
Danaher Schedules Second Quarter 2024 Earnings Conference Call
2024-06-19 11:30 ET
Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics
2024-06-05 11:00 ET
Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer
2024-05-09 11:00 ET
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
2024-05-07 20:45 ET
Danaher to Present at Bank of America Securities Healthcare Conference
2024-05-07 20:15 ET
Danaher Announces Quarterly Dividend
2024-05-03 13:06 ET
Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry
2024-04-23 10:00 ET
Danaher Reports First Quarter 2024 Results
2024-03-21 20:15 ET
Danaher Schedules First Quarter 2024 Earnings Conference Call
2024-02-27 21:15 ET
Danaher to Present at TD Cowen Health Care Conference
2024-02-22 21:15 ET
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
2024-02-21 21:15 ET
Danaher Announces Quarterly Dividend
2024-02-05 12:30 ET
Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development
2024-01-30 11:00 ET
Danaher Reports Fourth Quarter and Full Year 2023 Results
2024-01-09 12:30 ET
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
2024-01-08 21:15 ET
Danaher CEO to Comment on Financial Performance
2024-01-02 22:00 ET
Danaher to Present at J.P. Morgan Healthcare Conference
2023-12-21 21:30 ET
Danaher Schedules Fourth Quarter 2023 Earnings Conference Call
2023-12-06 12:30 ET
Danaher Completes Acquisition of Abcam
2023-12-05 21:30 ET
Danaher Announces Quarterly Dividend
2023-12-04 21:01 ET
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
2023-11-21 21:15 ET
Danaher to Present at Evercore ISI HealthCONx Conference
2023-11-17 12:00 ET
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023
2023-11-06 21:00 ET
Shareholders of Abcam Approve Proposed Acquisition by Danaher
2023-10-31 11:30 ET
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
2023-10-24 10:00 ET
Danaher Reports Third Quarter 2023 Results
2023-10-17 12:15 ET
Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine
2023-10-12 11:30 ET
Independent Directors of Abcam Highlight Compelling Reasons for Shareholders to Support Proposed Sale to Danaher
2023-10-05 12:00 ET
Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share
2023-09-30 12:00 ET
Danaher Corporation Completes Separation of Veralto Corporation
2023-09-26 20:15 ET
Danaher Schedules Third Quarter 2023 Earnings Conference Call
2023-09-19 11:43 ET
Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost
2023-09-12 20:30 ET
Danaher Announces Quarterly Dividend
2023-08-31 22:00 ET
Danaher and Veralto to Webcast Investor and Analyst Meeting
2023-08-28 11:35 ET
Danaher to acquire Abcam for $24.00 per Share
2023-08-28 11:30 ET
Danaher to Acquire Abcam
2023-08-28 ET
Danaher to acquire Abcam for $24.00 per Share
2023-08-25 20:30 ET
Danaher Declares pro Rata Dividend of Veralto Common Stock and Announces Expected "When-issued" Trading of Veralto Common Stock
2023-08-16 20:30 ET
Danaher Releases 2023 Sustainability Report
2023-07-25 16:00 ET
Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC
2023-07-25 15:00 ET
Beckman Coulter Receives FDA Clearance for DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance
2023-07-25 10:00 ET
Danaher Reports Second Quarter 2023 Results
2023-07-17 12:30 ET
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
2023-06-20 21:00 ET
Danaher Schedules Second Quarter 2023 Earnings Conference Call
2023-05-15 06:00 ET
Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance
2023-05-09 20:30 ET
Danaher Announces Quarterly Dividend
2023-05-03 22:00 ET
Danaher to Present at Bank of America Securities Health Care Conference
2023-05-01 11:32 ET
ALDEVRON ANNOUNCES EXPANSION OF mRNA PRODUCTION CAPABILITY
2023-04-25 10:00 ET
Danaher Reports First Quarter 2023 Results
2023-04-10 20:30 ET
Danaher Announces Conversion Date for Series B Mandatory Convertible Preferred Stock
2023-03-27 20:23 ET
Danaher Schedules First Quarter 2023 Earnings Conference Call
2023-03-07 13:00 ET
Danaher Partners with the University of Pennsylvania's Center for Cellular Immunotherapies to Address Manufacturing Challenges Impacting the Uptake of Cell Therapies
2023-02-22 21:30 ET
Danaher Announces Quarterly Dividends
2023-02-08 14:00 ET
Danaher Announces New Environmental and Applied Solutions Company to Be Named Veralto
2023-01-24 11:00 ET
Danaher Reports Fourth Quarter and Full Year 2022 Results
2023-01-09 21:15 ET
Danaher CEO to Comment on Financial Performance
2023-01-03 21:30 ET
Danaher to Present at J.P. Morgan Healthcare Conference
2022-12-27 21:30 ET
Danaher Schedules Fourth Quarter 2022 Earnings Conference Call
2022-12-06 21:20 ET
Danaher Announces Quarterly Dividends
2022-11-22 21:45 ET
Danaher to Present at Evercore ISI HealthCONx Conference
2022-11-15 12:00 ET
Cepheid Launches Multiplex Vaginal Panel (MVP) to Support More Accurate Women's Health Diagnosis in U.S.
2022-11-10 21:15 ET
Danaher Launches Beacon Initiative and Its First Partnership Focused on Gene Therapy Innovation
2022-10-20 10:00 ET
Danaher Reports Third Quarter 2022 Results
2022-10-05 20:30 ET
Danaher Releases 2022 Sustainability Report and Announces New Greenhouse Gas Emissions Reduction Target
2022-09-20 20:30 ET
Danaher Schedules Third Quarter 2022 Earnings Conference Call
2022-09-14 20:15 ET
Danaher Announces Intention to Separate Environmental & Applied Solutions Segment to Create an Independent, Publicly Traded Company
2022-09-14 20:15 ET
Danaher CEO to Comment on Financial Performance
2022-09-13 20:15 ET
Danaher Announces Quarterly Dividends
2022-09-01 21:00 ET
Danaher to Webcast Bioprocessing Investor and Analyst Meeting at Cytiva
2022-07-25 11:41 ET
Beckman Coulter Partners with Mass General and BARDA to Identify Severe Pediatric Infections in Emergency Departments
2022-07-21 10:00 ET
Danaher Reports Second Quarter 2022 Results
2022-06-29 21:00 ET
Danaher Announces Appointment of Feroz Dewan to Danaher Board
2022-06-21 20:30 ET
Danaher Schedules Second Quarter 2022 Earnings Conference Call
2022-06-06 16:00 ET
SCIEX Launches the New Cornerstone of Software Ecosystem - SCIEX OS 3.0
2022-06-06 16:00 ET
SCIEX Launches the Next Generation of Data Independent Acquisition With Zeno SWATH DIA at ASMS 2022
2022-05-12 20:30 ET
Danaher Joins Bespoke Gene Therapy Consortium (BGTC) for Rare Diseases
2022-05-10 20:15 ET
DANAHER ANNOUNCES QUARTERLY DIVIDENDS
2022-05-09 15:00 ET
RNA 9000 Purity and Integrity Kit Allows for Critical High-Resolution Analysis for mRNA Therapeutics
2022-05-04 20:30 ET
Danaher To Present At Bank Of America Securities Health Care Conference
2022-04-21 10:00 ET
Danaher Reports First Quarter 2022 Results
2022-04-12 20:30 ET
Danaher Announces Conversion Date For Series A Mandatory Convertible Preferred Stock
2022-03-28 13:00 ET
Catalytic Data Science Joins Integrated DNA Technologies Align Program
2022-03-21 20:30 ET
Danaher Schedules First Quarter 2022 Earnings Conference Call
2022-03-21 12:55 ET
Integrated DNA Technologies Adds MLL Munich Leukemia Laboratory to Align Program
2022-03-01 21:30 ET
DANAHER TO PRESENT AT COWEN HEALTHCARE CONFERENCE
2022-02-23 21:15 ET
Danaher Announces Quarterly Dividends
2022-01-27 11:00 ET
Danaher Reports Fourth Quarter And Full Year 2021 Results
2022-01-11 13:00 ET
Pall Corporation's new Supralon™ Filter Element Advances Equipment Protection and Reduces Energy Costs
2022-01-11 11:30 ET
Danaher CEO to Comment on Financial Performance
2022-01-04 21:15 ET
Danaher To Present At J.P. Morgan Healthcare Conference
2021-12-27 21:15 ET
DANAHER SCHEDULES FOURTH QUARTER 2021 EARNINGS CONFERENCE CALL
2021-12-07 21:15 ET
Danaher Announces Quarterly Dividends
2021-12-02 02:15 ET
Danaher Announces Pricing Of Senior Notes Offering
2021-11-30 15:00 ET
IDBS Polar™ Insight Brings Advanced Data Analytics and Visualization to BioPharma Lifecycle Management
2021-11-29 12:00 ET
Danaher Announces Redemption Of Senior Notes
2021-11-23 21:15 ET
Danaher To Present At Evercore ISI HealthCONx Conference
2021-10-21 10:00 ET
Danaher Reports Third Quarter 2021 Results
2021-10-14 12:10 ET
Cepheid recibe el marcado CE para Xpert Xpress CoV-2/Flu/RSV plus
2021-10-12 20:30 ET
Danaher Releases 2021 Sustainability Report; Building A Strong Foundation Of Sustainability
2021-09-28 10:00 ET
Beckman Coulter's new urinalysis solution improves laboratory workflow by significantly reducing manual reviews to 4%(1) and cutting sample processing time by up to 78%(2)
2021-09-21 20:15 ET
Danaher Schedules Third Quarter 2021 Earnings Conference Call
2021-09-14 20:15 ET
Danaher Announces Quarterly Dividends
2021-09-01 16:14 ET
Demaris Mills Appointed President of IDT
2021-09-01 15:00 ET
SCIEX Builds on Cadence of Innovation in Biopharma With Biologics Explorer
2021-09-01 15:00 ET
SCIEX Presents Industry First Multi-Capillary System for CE-SDS, the BioPhase 8800 System
2021-08-30 20:15 ET
Danaher Completes Acquisition of Aldevron
2021-08-25 20:30 ET
Danaher To Webcast Investor And Analyst Meeting
2021-08-24 12:30 ET
Danaher Announces Human Resources And Accounting Leadership Transition Plans
2021-07-27 06:05 ET
Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions
2021-07-26 12:30 ET
Beckman Coulter to Distribute BNP Cardiac Assay to Customers
2021-07-22 10:00 ET
Danaher Reports Second Quarter 2021 Results
2021-07-01 12:00 ET
Pall Corporation Secures Multi-Million Dollar Contract With Exothera
2021-06-22 20:15 ET
Danaher Schedules Second Quarter 2021 Earnings Conference Call
2021-06-17 15:00 ET
SCIEX OS Introduces New Software With OneOmics Suite and Molecule Profiler App
2021-06-17 15:00 ET
SCIEX Presents New Accurate Mass Instrument, The ZenoTOF 7600 System
2021-06-17 13:00 ET
Danaher To Acquire Aldevron
2021-06-07 20:15 ET
Danaher To Present At Goldman Sachs Global Healthcare Conference
2021-05-27 20:15 ET
Danaher To Present At Jefferies Healthcare Conference
2021-05-13 20:30 ET
Danaher Announces Appointment of A. Shane Sanders to Danaher Board
2021-05-05 20:15 ET
Danaher Announces Quarterly Dividends
2021-05-04 21:45 ET
Danaher To Present At Bank Of America Healthcare Conference
2021-04-26 13:00 ET
Danaher Announces Renowned Scientists To Join New Scientific Advisory Board
2021-04-22 10:00 ET
Danaher Reports First Quarter 2021 Results
2021-04-13 11:00 ET
Danaher Provides Update On First Quarter 2021 Financial Performance
2021-04-01 12:00 ET
Pall Corporation Expands Global Production Capacity
2021-03-25 21:00 ET
Danaher Schedules First Quarter 2021 Earnings Conference Call
2021-03-23 17:53 ET
/C O R R E C T I O N -- Beckman Coulter Diagnostics/
2021-03-18 18:14 ET
Beckman Coulter Offers $4/High-throughput Antigen Test to Support U.S. Government Initiative to Expand COVID-19 Testing
2021-03-11 14:00 ET
IDT Acquires Swift Biosciences, a Pioneer in the Development of Next-Generation Sequencing (NGS) Library Preparation Genomics Kits for Academic, Translational, and Clinical Research
2021-03-04 21:15 ET
Danaher To Present At Barclays Global Healthcare Conference
2021-02-23 21:15 ET
Danaher Announces Quarterly Dividends
2021-02-22 21:15 ET
Danaher To Present At Cowen Healthcare Conference
2021-02-01 05:01 ET
Cytiva acquires Vanrx Pharmasystems, Canadian aseptic filling innovator
2021-01-28 11:00 ET
Danaher Reports Fourth Quarter And Full Year 2020 Results
2021-01-25 16:44 ET
Beckman Coulter brings the productivity and efficiency benefits of large volume hematology analyzers to small- and medium-sized labs
2021-01-13 11:59 ET
Danaher CEO To Comment On Financial Performance
2021-01-07 21:15 ET
Danaher To Present At J.P. Morgan Healthcare Conference
2021-01-07 21:15 ET
Danaher Schedules Fourth Quarter 2020 Earnings Conference Call
2020-12-21 21:15 ET
Danaher Announces Executive Appointment
2020-12-16 13:00 ET
Pall Corporation and Single Use Support Partner to Safeguard Storage and Transport Critical Biopharmaceuticals
2020-12-14 13:00 ET
Danaher announces leadership appointment
2020-12-08 21:15 ET
Danaher Announces Quarterly Dividend
2020-11-24 22:00 ET
Danaher To Present At Evercore ISI HealthCONx Conference
2020-11-23 13:00 ET
Beckman Coulter launches its semi-quantitative SARS-CoV-2 IgG II antibody test
2020-11-16 21:15 ET
Danaher To Present At Wolfe Research Healthcare Conference
2020-11-10 21:15 ET
Danaher Releases 2020 Sustainability Report
2020-11-10 08:00 ET
Beckman Coulter launches its SARS-CoV-2 IgM antibody test in countries accepting CE Mark and will begin shipping to diagnostics labs
2020-10-27 08:00 ET
Cytiva strengthens support to diagnostics industry with new labs, services and supply chain enhancements
2020-10-22 10:00 ET
Danaher Reports Third Quarter 2020 Results
2020-10-15 12:00 ET
Beckman Coulter receives BARDA funding to validate Monocyte Distribution Width in the rapid detection of Multisystem Inflammatory Syndrome (MIS-C), a severe COVID-19 complication in Children
2020-10-09 12:00 ET
Beckman Coulter SARS-CoV-2 IgM Antibody Test Receives FDA Emergency Use Authorization
2020-10-07 20:15 ET
Danaher Schedules Third Quarter 2020 Earnings Conference Call
2020-10-06 11:00 ET
Danaher Announces Redemption Of Senior Notes
2020-09-30 01:30 ET
Danaher Announces Pricing Of Senior Notes Offering
2020-09-29 11:00 ET
Cepheid Receives Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV Combination Test
2020-09-25 21:45 ET
Correction Notice To Press Release Regarding Dividend Amount
2020-09-15 20:15 ET
Danaher Announces Quarterly Dividend
2020-09-15 13:00 ET
Beckman Coulter Lauded by Frost & Sullivan for Accelerating Sepsis Detection with the DxH 690T
2020-09-13 19:00 ET
5 years, 500 million USD, and nearly 1,000 people: Cytiva invests for global capacity expansion
2020-09-01 20:15 ET
Danaher Appoints Rainer M. Blair As President And CEO
2020-08-24 12:00 ET
Beckman Coulter Launches SARS-CoV-2 IgM Antibody Test and will begin shipping to U.S. Diagnostics Labs
2020-07-23 12:00 ET
Beckman Coulter's Automated Blood Banking Analyzer Receives 510(k) FDA Clearance
2020-07-23 10:00 ET
Danaher Reports Second Quarter 2020 Results
2020-07-21 20:52 ET
Beckman Coulter Wins SelectScience Awards for Best New Clinical Instrumentation and Customer Service of the Year
2020-07-17 13:15 ET
Beckman Coulter Receives Nine IMV ServiceTrak™ Clinical Laboratory Awards
2020-07-16 11:00 ET
New Rapid Molecular Test For Tuberculosis Can Simultaneously Detect Resistance To First- And Second-Line Drugs
2020-07-13 20:15 ET
Danaher Schedules Second Quarter 2020 Earnings Conference Call
2020-07-09 15:00 ET
Fully Integrated SCIEX OS Software Launches at Virtual Product Experience
2020-06-09 11:00 ET
Cepheid Announces Development of Four-in-One Combination Test for SARS-CoV-2, Flu A, Flu B and RSV
2020-05-12 20:10 ET
Danaher Announces Closing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering
2020-05-08 05:15 ET
Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering
2020-05-07 12:40 ET
Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock
2020-05-06 20:10 ET
Danaher Reports First Quarter 2020 Results
2020-05-06 20:10 ET
Danaher Corporation Announces CEO Transition
2020-05-05 20:10 ET
Danaher Announces Quarterly Dividend
2020-04-30 13:00 ET
Danaher Completes Sale Of Certain Businesses To Sartorius AG To Satisfy Regulatory Requirement For Cytiva Acquisition
2020-04-17 10:45 ET
Danaher Corporation Changes Its Annual Shareholders Meeting To A Virtual Format
2020-04-13 10:45 ET
Danaher Provides Update On First Quarter 2020 Financial Performance And Schedules First Quarter Earnings Conference Call
2020-04-03 20:45 ET
Danaher Prices Reopening Of Euro-Denominated Senior Notes
2020-03-31 22:00 ET
Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences; Business Will Be Called Cytiva
2020-03-26 01:15 ET
Danaher Announces Pricing of Euro-Denominated Senior Notes Offering
2020-03-21 13:00 ET
Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test
2020-03-19 22:50 ET
Danaher Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of The Biopharma Business Of General Electric Life Sciences
2020-02-20 21:15 ET
Danaher Announces Quarterly Dividend
2020-01-30 11:00 ET
Danaher Reports Fourth Quarter and Full Year 2019 Results
2020-01-23 22:30 ET
Danaher Announces Updated Time For Fourth Quarter 2019 Earnings Conference Call
2020-01-13 21:15 ET
Danaher CEO To Comment On Financial Performance
2020-01-07 21:15 ET
Danaher Schedules Fourth Quarter 2019 Earnings Conference Call
2019-12-16 11:00 ET
Danaher Announces Preliminary Results Of Envista Exchange Offer
2019-12-11 21:42 ET
Danaher Announces Final Exchange Ratio Of 5.5784 for Envista Exchange Offer
2019-11-27 21:30 ET
Danaher To Present At Evercore ISI HealthCONx Conference
2019-11-15 11:30 ET
Danaher Will Commence Exchange Offer Related To Divestiture Of Its Remaining Interest In Envista Through A Split-Off
2019-11-15 11:30 ET
Envista To File Registration Statement In Connection With Danaher Exchange Offer Announcement
2019-11-13 21:15 ET
Danaher Announces Appointment of Jessica L. Mega, MD, MPH and Pardis C. Sabeti MD, D.Phil to Danaher Board
2019-10-30 03:01 ET
Danaher Announces Pricing Of Senior Notes Offering
2019-10-28 20:15 ET
Danaher To Present At Baird Global Industrial Conference
2019-10-21 05:00 ET
Danaher Reaches Agreement To Sell Certain Businesses To Sartorius AG As Part Of The GE Biopharma Acquisition Regulatory Process
2019-03-19 20:15 ET
Danaher Schedules First Quarter 2019 Earnings Conference Call
2019-03-08 21:15 ET
Danaher Announces Quarterly Dividend
2019-03-01 22:00 ET
Danaher Announces Closing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering
2019-02-27 04:15 ET
Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering

SEC forms

Show financial reports only

SEC form 8
2026-04-29 20:14 ET
Danaher published news for 2026 q1
SEC form 8
2026-04-29 20:14 ET
Danaher published news for 2026 q1
SEC form 8
2026-04-29 20:14 ET
Danaher published news for 2026 q1
SEC form 8
2026-04-29 20:14 ET
Danaher published news for 2026 q1
SEC form 8
2026-04-20 21:44 ET
Danaher published news for 2026 q1
SEC form 8
2026-04-20 21:44 ET
Danaher published news for 2026 q1
SEC form 10
2026-04-20 21:40 ET
Danaher published news for 2026 q1
SEC form 10
2026-02-24 21:36 ET
Danaher published news for 2025 q4
SEC form 8
2026-02-17 13:08 ET
Danaher published news for 2025 q4
SEC form 8
2026-02-17 13:08 ET
Danaher published news for 2025 q4
SEC form 8
2026-01-27 17:37 ET
Danaher published news for 2025 q4
SEC form 8
2026-01-27 17:37 ET
Danaher reported for 2025 q4
SEC form 8
2026-01-12 14:07 ET
Danaher published news for 2025 q4
SEC form 8
2026-01-12 14:07 ET
Danaher published news for 2025 q4
SEC form 8
2026-01-12 14:07 ET
Danaher published news for 2025 q4
SEC form 10
2025-10-20 21:56 ET
Danaher reported for 2025 q3
SEC form 8
2025-10-20 21:39 ET
Danaher published news for 2025 q3
SEC form 8
2025-10-20 21:39 ET
Danaher published news for 2025 q3
SEC form 10
2025-07-22 00:00 ET
Danaher published news for 2025 q2
SEC form 10
2025-07-21 22:39 ET
Danaher reported for 2025 q2
SEC form 8
2025-07-21 21:47 ET
Danaher published news for 2025 q2
SEC form 8
2025-07-21 21:47 ET
Danaher published news for 2025 q2
SEC form 8
2025-05-08 20:36 ET
Danaher published news for 2025 q1
SEC form 8
2025-04-22 10:08 ET
Danaher published news for 2025 q1
SEC form 8
2025-04-22 10:08 ET
Danaher published news for 2025 q1
SEC form 10
2025-04-22 10:03 ET
Danaher reported for 2025 q1
SEC form 10
2025-04-22 00:00 ET
Danaher published news for 2025 q1
SEC form 10
2025-02-20 21:18 ET
Danaher published news for 2024 q4
SEC form 10
2025-02-20 00:00 ET
Danaher reported for 2024 q4
SEC form 8
2025-01-28 17:45 ET
Danaher published news for 2024 q4
SEC form 8
2025-01-28 17:45 ET
Danaher reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Danaher published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Danaher published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Danaher published news for 2024 q4
SEC form 10
2024-10-22 00:00 ET
Danaher reported for 2024 q3
SEC form 8
2024-10-21 17:47 ET
Danaher published news for 2024 q3
SEC form 8
2024-10-21 17:47 ET
Danaher published news for 2024 q3
SEC form 10
2024-10-21 17:38 ET
Danaher published news for 2024 q3
SEC form 10
2024-07-23 00:00 ET
Danaher reported for 2024 q2
SEC form 8
2024-07-22 17:47 ET
Danaher published news for 2024 q2
SEC form 8
2024-07-22 17:47 ET
Danaher reported for 2024 q2
SEC form 10
2024-07-22 17:41 ET
Danaher published news for 2024 q2
SEC form 10
2024-04-23 00:00 ET
Danaher published news for 2024 q1
SEC form 8
2024-04-22 18:00 ET
Danaher published news for 2024 q1
SEC form 8
2024-04-22 18:00 ET
Danaher published news for 2024 q1
SEC form 10
2024-04-22 17:53 ET
Danaher reported for 2024 q1
SEC form 10
2024-02-21 00:00 ET
Danaher reported for 2023 q4
SEC form 8
2024-01-30 00:00 ET
Danaher published news for 2023 q4
SEC form 8
2024-01-30 00:00 ET
Danaher reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Danaher published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Danaher published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Danaher published news for 2023 q4
SEC form 10
2023-10-24 00:00 ET
Danaher published news for 2023 q3
SEC form 8
2023-10-23 17:47 ET
Danaher reported for 2023 q3
SEC form 10
2023-10-23 17:43 ET
Danaher reported for 2023 q3
SEC form 10
2023-07-25 00:00 ET
Danaher published news for 2023 q2
SEC form 8
2023-07-25 00:00 ET
Danaher reported for 2023 q2
SEC form 6
2023-07-24 17:59 ET
Danaher published news for 2023 q2
SEC form 10
2023-07-24 17:46 ET
Danaher reported for 2023 q2
SEC form 6
2023-06-21 17:27 ET
Danaher published news for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Danaher published news for 2023 q1
SEC form 10
2023-04-25 00:00 ET
Danaher reported for 2023 q1
SEC form 8
2023-04-25 00:00 ET
Danaher reported for 2023 q1
SEC form 10
2023-02-22 16:40 ET
Danaher published news for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Danaher reported for 2022 q4
SEC form 8
2023-01-24 00:00 ET
Danaher reported for 2022 q4
SEC form 6
2023-01-23 19:58 ET
Danaher published news for 2022 q4
SEC form 6
2023-01-18 17:08 ET
Danaher published news for 2022 q4
SEC form 6
2023-01-09 16:17 ET
Danaher published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Danaher published news for 2022 q4
SEC form 6
2022-12-07 16:58 ET
Danaher published news for 2022 q3
SEC form 10
2022-10-20 00:00 ET
Danaher reported for 2022 q3
SEC form 8
2022-10-20 00:00 ET
Danaher reported for 2022 q3
SEC form 6
2022-10-19 17:58 ET
Danaher published news for 2022 q3
SEC form 10
2022-10-19 17:49 ET
Danaher published news for 2022 q3
SEC form 10
2022-07-21 00:00 ET
Danaher reported for 2022 q2
SEC form 6
2022-07-20 17:49 ET
Danaher published news for 2022 q2
SEC form 10
2022-07-20 17:46 ET
Danaher published news for 2022 q2
SEC form 6
2022-06-29 17:04 ET
Danaher published news for 2022 q1
SEC form 6
2022-06-06 16:59 ET
Danaher published news for 2022 q1
SEC form 6
2022-06-06 16:54 ET
Danaher published news for 2022 q1
SEC form 6
2022-05-12 17:11 ET
Danaher published news for 2022 q1
SEC form 10
2022-04-21 00:00 ET
Danaher reported for 2022 q1
SEC form 8
2022-04-21 00:00 ET
Danaher reported for 2022 q1
SEC form 6
2022-04-20 18:04 ET
Danaher published news for 2022 q1
SEC form 10
2022-04-20 17:52 ET
Danaher published news for 2022 q1
SEC form 6
2022-04-01 07:05 ET
Danaher published news for 2022 q1
SEC form 6
2022-03-30 07:30 ET
Danaher published news for 2021 q4
SEC form 10
2022-02-23 16:49 ET
Danaher published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Danaher published news for 2021 q4
SEC form 8
2022-01-27 00:00 ET
Danaher published news for 2021 q4
SEC form 6
2022-01-26 17:46 ET
Danaher published news for 2021 q4
SEC form 6
2022-01-11 07:28 ET
Danaher published news for 2021 q4
SEC form 8
2022-01-11 00:00 ET
Danaher published news for 2021 q4
SEC form 6
2021-12-10 16:36 ET
Danaher published news for 2021 q3
SEC form 6
2021-12-08 17:06 ET
Danaher published news for 2021 q3
SEC form 10
2021-10-21 00:00 ET
Danaher published news for 2021 q3
SEC form 8
2021-10-21 00:00 ET
Danaher published news for 2021 q3
SEC form 6
2021-10-20 18:00 ET
Danaher published news for 2021 q3
SEC form 10
2021-10-20 17:49 ET
Danaher published news for 2021 q3
SEC form 6
2021-09-15 17:13 ET
Danaher published news for 2021 q2
SEC form 6
2021-08-24 16:15 ET
Danaher published news for 2021 q2
SEC form 6
2021-07-26 08:36 ET
Danaher published news for 2021 q2
SEC form 10
2021-07-22 00:00 ET
Danaher published news for 2021 q2
SEC form 8
2021-07-22 00:00 ET
Danaher published news for 2021 q2
SEC form 6
2021-07-21 18:11 ET
Danaher published news for 2021 q2
SEC form 10
2021-07-21 17:58 ET
Danaher published news for 2021 q2
SEC form 6
2021-07-13 17:09 ET
Danaher published news for 2021 q2
SEC form 6
2021-06-11 16:46 ET
Danaher published news for 2021 q1
SEC form 6
2021-06-11 16:41 ET
Danaher published news for 2021 q1
SEC form 6
2021-05-18 17:23 ET
Danaher published news for 2021 q1
SEC form 6
2021-05-18 17:14 ET
Danaher published news for 2021 q1
SEC form 6
2021-05-13 16:38 ET
Danaher published news for 2021 q1
SEC form 6
2021-05-07 08:16 ET
Danaher published news for 2021 q1
SEC form 10
2021-04-22 00:00 ET
Danaher published news for 2021 q1
SEC form 8
2021-04-22 00:00 ET
Danaher published news for 2021 q1
SEC form 6
2021-04-21 18:20 ET
Danaher published news for 2021 q1
SEC form 10
2021-04-21 18:11 ET
Danaher published news for 2021 q1
SEC form 6
2021-04-13 07:12 ET
Danaher published news for 2021 q1
SEC form 6
2021-03-25 07:30 ET
Danaher published news for 2020 q4
SEC form 10
2021-02-24 19:13 ET
Danaher published news for 2020 q4
SEC form 6
2021-01-27 18:19 ET
Danaher published news for 2020 q4
SEC form 6
2021-01-13 07:23 ET
Danaher published news for 2020 q4
SEC form 6
2021-01-05 17:07 ET
Danaher published news for 2020 q4
SEC form 6
2020-10-21 18:28 ET
Danaher published news for 2020 q3
SEC form 10
2020-10-21 18:15 ET
Danaher published news for 2020 q3
SEC form 6
2020-10-06 16:18 ET
Danaher published news for 2020 q3